Astemizole

證據等級: L5

預測適應症: 1 個

Astemizole: From Allergic Rhinitis to Rosacea Conjunctivitis

One-Sentence Summary

Astemizole is a second-generation H1 antihistamine historically used for allergic conditions such as allergic rhinitis and urticaria, but withdrawn from global markets in 1999 due to life-threatening cardiac toxicity. The TxGNN model predicts it may have potential in Rosacea Conjunctivitis, with a high computational score of 99.78% — however, no clinical trials and no published literature currently support this direction, making this a purely model-driven prediction.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis, urticaria (antihistamine; not listed in India registry — drug is not marketed)
Predicted New Indication	Rosacea Conjunctivitis
TxGNN Prediction Score	99.78%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Astemizole is a second-generation H1 histamine receptor antagonist (antihistamine). Its mechanism relies on selectively blocking H1 receptors, thereby suppressing the inflammatory cascade triggered by histamine released from mast cells — without the sedation profile of first-generation antihistamines.

Rosacea conjunctivitis is a form of ocular inflammation associated with rosacea, a chronic skin condition with a prominent inflammatory component. Conjunctival mast cells release histamine upon activation, contributing to redness, itching, and irritation. On mechanistic grounds, H1 blockade could theoretically dampen this histamine-mediated ocular inflammation, providing the biological rationale for TxGNN’s prediction.

However, this theoretical link is overshadowed by a critical safety reality. Astemizole was withdrawn from the US FDA and EU markets in 1999 due to its blockade of the hERG cardiac potassium channel, leading to QTc interval prolongation and potentially fatal arrhythmias (Torsades de Pointes). With 276 known drug-drug interactions, it is classified as an extremely high-risk compound. The prediction score of 99.78%, while mathematically impressive, reflects graph-based structural similarity rather than clinical viability.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Astemizole currently holds no approved drug licenses in India. The drug is not marketed and has no active registrations on record.

Safety Considerations

Drug Interactions (276 total interactions identified):

Below are selected interactions of note, prioritised by severity:

Interacting Drug	Severity	Clinical Relevance
Clarithromycin	Major	CYP3A4 inhibition raises astemizole plasma levels → increased QTc risk
Aprepitant	Major	CYP3A4 inhibition → elevated astemizole exposure
Cimetidine	Major	Inhibits hepatic metabolism → QTc prolongation risk
Miconazole	Major	Antifungal CYP inhibition → cardiac arrhythmia risk
Dolasetron	Major	Additive QTc prolongation
Picosulfuric acid	Major	Electrolyte-mediated QTc potentiation
Polyethylene glycol (3350 with electrolytes)	Major	Electrolyte shifts → increased arrhythmia risk
Sodium sulfate	Major	Electrolyte disturbance interaction
Ondansetron	Moderate	Additive QTc effects (5-HT3 antagonist)
Palonosetron	Moderate	Additive QTc effects
Levofloxacin	Moderate	Fluoroquinolone-related QTc additive effect
Famotidine	Moderate	H2/H1 pathway overlap, QT monitoring advised
Loperamide	Moderate	Cardiac conduction caution

⚠️ Critical Safety Note: Astemizole’s hERG channel blockade and resultant QTc prolongation risk led to its global market withdrawal in 1999. It should be regarded as a withdrawn compound with an unacceptable cardiac safety profile for any new indication development without a specific cardiac risk mitigation programme.

Conclusion and Next Steps

Decision: Hold

Rationale: Although TxGNN assigns a high prediction score (99.78%) based on mechanistic graph proximity between H1 antagonism and histamine-mediated conjunctival inflammation, astemizole carries a black-box cardiac safety profile that resulted in its global withdrawal. With zero supporting clinical trials, zero published literature, 276 drug-drug interactions, and no India market presence, the benefit-risk ratio for pursuing this candidate is currently unfavourable.

To reconsider this direction, the following would be needed:

Cardiac safety re-evaluation: Evidence that a topical ophthalmic formulation achieves negligible systemic exposure, thereby circumventing QTc risk
Preclinical proof-of-concept: In vitro or in vivo data demonstrating efficacy in a rosacea conjunctivitis model
Regulatory pathway consultation: Assessment of whether the 1999 withdrawal creates insurmountable barriers to any new IND filing
Comparative analysis: Head-to-head mechanistic comparison against safer second-generation antihistamines (e.g., olopatadine, azelastine) already approved for ophthalmic use
MOA data gap resolution: Confirm via DrugBank API whether any additional pharmacological activity (beyond H1 antagonism) contributes to TxGNN’s prediction
Full safety document retrieval: Package insert warnings and contraindications should be sourced before any further development consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.